Howard Goldman, MD
Urology · Cleveland, OHNPI 1154386324
Payments from drug & device makers
Across 941 payments — averaging $794.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$370K
- AbbVie$138K
- Sumitomo Pharma America, Inc.$71K
- Laborie Medical Technologies Corp.$42K
- Bioness Inc$31K
- Astellas Pharma US Inc$29K
- plus $66K from 16 others
Across 3 payments — averaging $1632.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cook Research Incorporated$5K
What the payments were for
- Consulting fees$122,07317%
- Speaking & faculty fees$455,08663%
- Travel & lodging$88,65812%
- Food & beverage$23,9853%
- Education$31,1804%
- Entertainment$2780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 407 | $370,352 |
| AbbVie(2 entities) | 281 | $138,365 |
| Sumitomo Pharma America, Inc. | 39 | $70,535 |
| Laborie Medical Technologies Corp. | 12 | $41,615 |
| Bioness Inc | 4 | $31,343 |
| Astellas Pharma US Inc | 54 | $29,223 |
| Boston Scientific | 75 | $25,401 |
| Urovant Sciences Inc | 14 | $13,964 |
| Cook Research Incorporated | 6 | $9,310 |
| Ipsen Innovation | 1 | $6,847 |
| Bluewind Medical | 9 | $5,055 |
| Axonics, Inc. | 16 | $3,398 |
| Minze Health, Inc | 1 | $825 |
| Coloplast | 6 | $421 |
| C. R. Bard, Inc. & Subsidiaries | 7 | $295 |
| Bioventus LLC | 1 | $225 |
| Calyxo, Inc. | 1 | $81 |
| Bayer | 3 | $74 |
| Ferring Pharmaceuticals Inc. | 1 | $30 |
| Healthtronics Stone Solutions, LLC | 1 | $25 |
| Tolmar Pharmaceuticals, Inc. | 1 | $19 |
| Urocure LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$320,501
- BOTOX$123,442
- GEMTESA$76,106
- Stimrouter for pain$31,343
- MYRBETRIQ$28,321
- GENERAL PELVIC ORGAN PROLAPSE$6,725
- RENOVA$4,163
- UPSYLON$3,161
- Axonics r-SNM System$2,559
- BOTOX COSMETIC$2,000
- INTERSTIM ICON$1,375
- GENERAL KIDNEY STONE DISEASE$1,000
- GENERAL FEMALE SUI$963
- GENERAL - THERAPIES$899
- Minze Homeflow$825
- REVI$791
- Advantage System$522
- Bulkamid$380
- Axonics$368
- Stimrouter Implantable Kit$225
How this compares
$747,416 in reported general payments places this provider in the 95th percentile of 485 urology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 36 | $21,128 |
| Estradiol | 17 | $2,130 |
| Trospium Chloride | 30 | $1,751 |
| Trimethoprim | 16 | $472 |
| Oxybutynin Chloride ErOxybutynin Chloride | 21 | $318 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 11 | $68 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $29,223 | $21,12836 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 485 urology providers in Ohio.
Other urology in Cleveland
- Jihad KaoukCleveland$696K
- Raymond RackleyCleveland$695K
- Sandip VasavadaCleveland$512K
- Petar BajicCleveland$321K
- Sriharan SivalingamCleveland$282K
- Adonis HijazCleveland$263K
- Ruben OlivaresCleveland$184K
- Ahmed AboumohamedCleveland$139K
- Jorge Gutierrez AcevesCleveland$90K
- Samuel HaywoodCleveland$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.